CSL Expects Flat Revenue for Fiscal 2027 With Return to Profit Growth

MT Newswires Live08-18

CSL (ASX:CSL) expects fiscal 2027 revenue to be flat while making a return to profit growth after fiscal 2026 results beat estimates amid restructuring.

The biotechnology company reported $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago and beating analysts' estimates surveyed by FactSet of $6.27.

Revenue for the year was $15.8 billion, beating the estimate of $15.38 billion from analysts polled by FactSet, while paying restructuring costs of $799 million.

The biotechnology firm attributed the results to "strong fundamentals" of the plasma industry and said momentum is building behind its newer therapy products.

Looking ahead, CSL expects fiscal 2027 revenue to be flat with 5% growth in its underlying net profit after tax.

"CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals, a simplified business and targeted investment in our commercial capabilities and development programs," said Interim Chief Executive Officer Gordon Naylor.

Jefferies, commenting on the company's Behring business, said productivity gains were insufficient to offset lower revenue against the division's high fixed-cost base as the segment's gross margin declined 70 basis points to 49.6%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660645155?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 12:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660645155","market":"nz","top_or_hot":-1,"title":"CSL Expects Flat Revenue for Fiscal 2027 With Return to Profit Growth","media":"MT Newswires Live","content":"<html><body><p> CSL (ASX:CSL) expects fiscal 2027 revenue to be flat while making a return to profit growth after fiscal 2026 results beat estimates amid restructuring.</p><p>The biotechnology company reported $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago and beating analysts' estimates surveyed by FactSet of $6.27.</p><p>Revenue for the year was $15.8 billion, beating the estimate of $15.38 billion from analysts polled by FactSet, while paying restructuring costs of $799 million.</p><p>The biotechnology firm attributed the results to \"strong fundamentals\" of the plasma industry and said momentum is building behind its newer therapy products.</p><p>Looking ahead, CSL expects fiscal 2027 revenue to be flat with 5% growth in its underlying net profit after tax.</p><p>\"CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals, a simplified business and targeted investment in our commercial capabilities and development programs,\" said Interim Chief Executive Officer Gordon Naylor.</p><p>Jefferies, commenting on the company's Behring business, said productivity gains were insufficient to offset lower revenue against the division's high fixed-cost base as the segment's gross margin declined 70 basis points to 49.6%.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Expects Flat Revenue for Fiscal 2027 With Return to Profit Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Expects Flat Revenue for Fiscal 2027 With Return to Profit Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-18 12:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CSL (ASX:CSL) expects fiscal 2027 revenue to be flat while making a return to profit growth after fiscal 2026 results beat estimates amid restructuring.</p><p>The biotechnology company reported $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago and beating analysts' estimates surveyed by FactSet of $6.27.</p><p>Revenue for the year was $15.8 billion, beating the estimate of $15.38 billion from analysts polled by FactSet, while paying restructuring costs of $799 million.</p><p>The biotechnology firm attributed the results to \"strong fundamentals\" of the plasma industry and said momentum is building behind its newer therapy products.</p><p>Looking ahead, CSL expects fiscal 2027 revenue to be flat with 5% growth in its underlying net profit after tax.</p><p>\"CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals, a simplified business and targeted investment in our commercial capabilities and development programs,\" said Interim Chief Executive Officer Gordon Naylor.</p><p>Jefferies, commenting on the company's Behring business, said productivity gains were insufficient to offset lower revenue against the division's high fixed-cost base as the segment's gross margin declined 70 basis points to 49.6%.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL.AU","symbol_name":"CSL LIMITED","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2660645155","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660645155","pubTimestamp":1787027041,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL  expects fiscal 2027 revenue to be flat while making a return to profit growth after fiscal 2026 results beat estimates amid restructuring.The biotechnology company reported $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago and beating analysts' estimates surveyed by FactSet of $6.27.Revenue for the year was $15.8 billion, beating the estimate of $15.38 billion from analysts polled by FactSet, while paying restructuring costs of $799 million.The biotechnology firm attributed the results to \"strong fundamentals\" of the plasma industry and said momentum is building behind its newer therapy products.Looking ahead, CSL expects fiscal 2027 revenue to be flat with 5% growth in its underlying net profit after tax.\"CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals, a simplified business and targeted investment in our commercial capabilities and development programs,\" said Interim Chief Executive Of","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSL.AU":"CSL LIMITED","CSL":"卡莱尔伙伴"},"translate_title":"CSL 预计 2027 财年收入持平，利润恢复增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":1.5},"content_text":"CSL (ASX:CSL) expects fiscal 2027 revenue to be flat while making a return to profit growth after fiscal 2026 results beat estimates amid restructuring.The biotechnology company reported $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago and beating analysts' estimates surveyed by FactSet of $6.27.Revenue for the year was $15.8 billion, beating the estimate of $15.38 billion from analysts polled by FactSet, while paying restructuring costs of $799 million.The biotechnology firm attributed the results to \"strong fundamentals\" of the plasma industry and said momentum is building behind its newer therapy products.Looking ahead, CSL expects fiscal 2027 revenue to be flat with 5% growth in its underlying net profit after tax.\"CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals, a simplified business and targeted investment in our commercial capabilities and development programs,\" said Interim Chief Executive Officer Gordon Naylor.Jefferies, commenting on the company's Behring business, said productivity gains were insufficient to offset lower revenue against the division's high fixed-cost base as the segment's gross margin declined 70 basis points to 49.6%.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660645155","isCrawlerRequest":true}